Cellectar Biosciences, Inc.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
None right now.
Trials
- CLRBCellectar Biosciences, Inc.0Calm
Evaluation of Iopofosine I 131 vs. R-CD in WM Patients
Not started yetPhase 3219 patientsMain results: Jan 2032 - CLRBCellectar Biosciences, Inc.0Calm
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Running, no new patientsPhase 2120 patientsMain results: Jun 22, 2026
Key executives leaving
From the last 12 months of the company's SEC reports.
None found.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 0 purchases
No insider sales or purchases in the last 6 months.
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Shared quarterly resultsNews report (8-K)Aug 13, 2026
- Quarterly reportQuarterly report (10-Q)Aug 13, 2026
- An executive or board member joined or leftNews report (8-K)Jul 10, 2026
- Permission to sell new sharesPermission to sell new shares (S-1)May 19, 2026
- An executive or board member joined or leftNews report (8-K)May 18, 2026
Money left
Coming soon: how many months of cash the company has, from its quarterly reports.